SCHEMBL23601799

SCHEMBL23601799

CN(C(=O)OCc1ccccc1)c1cccc(Br)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.48
ALDH1A1 P00352 6/20 0.47
MAPT P10636 2/20 0.47
HPGD P15428 2/20 0.47
GLA P06280 1/20 0.46
LRRK2 Q5S007 1/20 0.46
MAOB P27338 1/20 0.45
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
CHRNB2 P17787 1/20 0.45
CHRNB4 P30926 1/20 0.45
CHRNA3 P32297 1/20 0.45
CHRNA4 P43681 1/20 0.45
CHRM2 P08172 2/20 0.43
CHRM1 P11229 2/20 0.43
CHRM3 P20309 2/20 0.43
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP12 P39900 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30013373 1.00 HCAR2 (0.48) HCAR2ALDH1A1MAPTHPGDGLA
SCHEMBL27558112 0.86 CHRNB2 (0.56) HCAR2ALDH1A1MAPTHPGDCHRNB2
SCHEMBL13915755 0.84 ALDH1A1 (0.46) ALDH1A1MAPTHPGDMAOBCHRNB2
SCHEMBL29793626 0.83 MAOB (0.55) ALDH1A1MAPTHPGDMAOBCHRNB2
SCHEMBL5263397 0.82 GLA (0.46) HCAR2ALDH1A1MAPTHPGDGLA
SCHEMBL7370517 0.82 ALDH1A1 (0.44) ALDH1A1MAPTHPGDCHRNB2CHRNB4
SCHEMBL2615683 0.82 ALDH1A1 (0.47) ALDH1A1MAPTHPGDMAOBCHRNB2
SCHEMBL31279443 0.82 RIPK1 (0.54) HCAR2ALDH1A1HPGDGLAMAOB
SCHEMBL9837062 0.80 ALDH1A1 (0.42) ALDH1A1MAPTHPGDCHRNB2CHRNB4
SCHEMBL27951862 0.80 ALDH1A1 (0.51) ALDH1A1MAPTLMNAHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4652161-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS Uppthera, Inc. (KR) 2025-11-26 EP disclosed
EP-4539849-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 Therapeutics, Inc. (US) 2025-04-23 EP disclosed
WO-2024155112-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS UPPTHERA, INC. (KR) 2024-07-25 WO disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 CN disclosed
WO-2023244764-A1 COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 C4 THERAPEUTICS, INC. (US) 2023-12-21 WO disclosed
CN-115362003-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2022-11-18 CN disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK HCAR2 2854/4885ALDH1A1 4095/4885MAPT 4206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.